What is the appropriate management of cholestatic hepatitis in a patient with psoriasis?

Management of Cholestatic Hepatitis in Psoriasis

Immediately discontinue any hepatotoxic psoriasis medications (particularly methotrexate, retinoids, or cyclosporin) and initiate ursodeoxycholic acid (UDCA) 15 mg/kg daily while investigating the underlying cause of cholestasis.

Initial Assessment and Causality Determination

The first critical step is determining whether cholestasis is drug-induced or represents a concurrent autoimmune/inflammatory process:

Immediate Diagnostic Workup

• Abdominal ultrasound to exclude biliary obstruction 1
• Autoimmune panel: ANA, anti-smooth muscle antibodies (ASMA), anti-mitochondrial antibodies (AMA) to identify primary biliary cholangitis or autoimmune hepatitis 2, 3
• Viral hepatitis serologies (HBV, HCV) 4
• Review medication history with temporal relationship to liver enzyme elevation 1
• Liver biopsy if diagnosis unclear or cholestasis persists beyond 3 months after drug withdrawal 1

Common Causes in Psoriasis Patients

The evidence reveals three primary etiologies:

1. Drug-induced cholestasis (57% of cases) - most common, particularly from methotrexate, retinoids, and cyclosporin 4
2. NAFLD (22% of cases) - associated with metabolic syndrome 5, 4
3. Neutrophilic cholangitis - rare but specific to generalized pustular psoriasis 6, 4

Treatment Algorithm

Step 1: Drug Withdrawal

Stop all hepatotoxic systemic psoriasis medications immediately 1. The guidelines emphasize that drug-induced cholestasis has no effective treatment except withdrawal 1. Monitor liver enzymes weekly initially 7.

Critical caveat: If on systemic corticosteroids, do NOT abruptly discontinue as this may precipitate erythrodermic or generalized pustular psoriasis 7. Taper gradually while managing cholestasis.

Step 2: Initiate UDCA Therapy

Start ursodeoxycholic acid (UDCA) 15 mg/kg daily for 24 weeks 8. Evidence shows UDCA:

• Normalizes hepatic steatosis index
• Reduces biliary sludge
• Stabilizes liver fibrosis
• Achieves better outcomes than phosphogliv in psoriasis patients 8

UDCA benefits two-thirds of drug-induced cholestasis cases 1 and is standard treatment for primary biliary cholangitis 2.

Step 3: Manage Underlying Psoriasis

For generalized pustular psoriasis with cholestasis:

• Intravenous methylprednisolone for acute severe exacerbations with cholestasis 9
• Spesolimab 900 mg single dose - newer evidence shows rapid resolution within 48 hours, safe in patients with concurrent hepatitis 10
• Acitretin for maintenance after cholestasis resolves, though monitor closely as it can cause hepatotoxicity 9, 10

For chronic plaque psoriasis requiring systemic therapy:

• Biologic agents (TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors) are preferred as they have lower hepatotoxicity risk 11, 2
• Cyclosporin may be considered if autoimmune hepatitis is confirmed, as it can treat both conditions simultaneously 3, but requires sophisticated renal monitoring 7

Step 4: Address Specific Complications

If neutrophilic cholangitis (in pustular psoriasis):

• Liver biopsy shows neutrophilic infiltrate in bile ducts 6
• Responds to systemic corticosteroids 9, 6
• May require long-term immunosuppression

If primary biliary cholangitis:

• Positive AMA, elevated alkaline phosphatase
• UDCA is standard long-term therapy 2
• Can coexist with psoriasis as separate autoimmune condition

If autoimmune hepatitis:

• Positive ANA/ASMA, elevated transaminases
• May require corticosteroids plus azathioprine or cyclosporin 3

Monitoring Protocol

During acute cholestasis:

• Liver function tests weekly until normalization 7, 1
• Most drug-induced cases normalize within 3 months 1

Long-term monitoring:

• Liver enzymes every 1-2 months once stable 7
• Screen for NAFLD with ultrasound and consider transient elastography if metabolic risk factors present 5
• Monitor for hepatic fibrosis, especially if cumulative methotrexate exposure >3.5-4g 11

Critical Pitfalls to Avoid

1. Do not rechallenge with the offending drug - potentially harmful and unethical 1
2. Do not assume all elevated liver enzymes are drug-related - 22% have underlying NAFLD, and rare cases represent autoimmune cholangitis 4
3. Do not use methotrexate in patients with significant hepatic damage - absolute contraindication 7
4. Do not overlook metabolic syndrome - psoriasis patients have 1.97-fold increased risk of NAFLD 5
5. Do not delay liver biopsy if cholestasis persists >3 months or is severe/progressive 1

Prognosis

Drug-induced cholestatic injury generally has good prognosis after withdrawal 1, with most cases resolving within 3 months. However, rare cases develop vanishing bile duct syndrome requiring transplantation 1. NAFLD-related transaminase elevations tend to fluctuate and require long-term management 4. Neutrophilic cholangitis in pustular psoriasis responds promptly to corticosteroids but may recur with disease flares 9, 6.